ENGLEWOOD, Colo., May 9, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held May 14-15, 2024.
Zynex's presentation will be held in person and webcast live on May 15 at 3:05 PM ET at the InterContinental Barclay Hotel in New York, NY. You can listen to the webcast at Zynex Investor Presentation Webcast. Dan Moorhead, CFO, will be available for one-on-one meetings on May 15.
To receive additional information, register to attend, or schedule a one-on-one meeting, email Mary Fleming at This email address is being protected from spambots. You need JavaScript enabled to view it. or Jennifer Nguyen at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$2.51 |
Daily Change: | 0.11 4.58 |
Daily Volume: | 244,521 |
Market Cap: | US$79.940M |
June 30, 2025 April 29, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load